热门资讯> 正文
展望Therapeutics非GAAP每股收益为-0.83美元,击败0.01美元
2024-08-14 19:24
- Outlook Therapeutics press release (NASDAQ:OTLK): Q3 Non-GAAP EPS of -$0.83 beats by $0.01.
- As of June 30, 2024, Outlook Therapeutics had cash and cash equivalents of $32.0 million.
More on Outlook Therapeutics
- Outlook Therapeutics: Worth A Good Strong Look After CRL
- Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market
- Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
- Outlook Therapeutics announces UK marketing authorization of its wet AMD treatment
- Outlook gets EU approval for Lytenava for wet AMD
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。